Skip to main content

Table 1 Clinicopathologic characteristics

From: Development and validation of nomograms to intraoperatively predict metastatic patterns in regional lymph nodes in patients diagnosed with esophageal cancer

  Number (percentage)/Median (range)   
  Total patients Training cohort Validation cohort  
Variables (n = 693) (n = 487) (n = 206) P value
Age(years) 64 (41–84) 64 (42–84) 64 (41–82) 0.908
Sex (Female/Male) 164 (23.7%)/529 (76.3%) 125 (25.7%)/362 (74.3%) 39 (18.9%)/167 (81.1%) 0.063
Smoke (1:Yes/ 0:No) 319 (46.3%)/370 (53.7%) 237 (48.7%)/250 (51.3%) 82 (23.7%)/120 (76.3%)
Missing 4 (1%)
0.054
Alcohol (1:Yes/ 0:No) 256 (37.2%)/432 (62.8%) 192 (39.4%)/295 (60.6%) 64 (31.8%)/137 (68.2%)
Missing 5 (2%)
0.069
Gastritis/Esophagitis (1:Yes/ 0:No) 22 (3.2%)/664 (96.8%) 13 (2.7%)/474 (97.3%) 9 (4.5%)/190 (95.5%)
Missing 7 (3%)
0.140
Diabetes (1:Yes/ 0:No) 41 (6%)/647 (94%) 27 (5.5%)/460 (94.5%) 14 (7%)/187 (93%)
Missing 5 (2%)
0.481
Tumor History (1:Yes/ 0:No) 17 (2.5%)/671 (97.5%) 13 (2.7%)/474 (97.3%) 14 (2%)/187 (98%)
Missing 5 (2%)
0.789
Family History Of Tumor (1:Yes/ 0:No) 75 (10.9%)/613 (89.1%) 60 (12.3%)/427 (87.7%) 15 (7.5%)/186 (92.5%)
Missing 5 (2%)
0.080
length of Tumor (cm) 3.36 (3.17–3.56) 3.37 (3.13–3.59) 3.36 (2.97–3.76) 0.996
Blood Type (A, B, AB, O) 214 (31.8%)/269 (40%) /0 (0%)/190 (28.2%) 138 (29.1%)/200 (42.1%) /0 (0%)/137 (28.8%)
Missing 12 (2%)
76 (38.4%)/69 (34.8%)/ 0 (0%)/53 (26.8%)
Missing 8 (4%)
0.077
Neutrophil(G) (1:> 3.3/0:< 3.3)109/L 349 (50.8%)/338 (49.2%) 238 (49.5%)/243 (50.5%)
Missing 6 (1%)
111 (53.9%)/95 (46.1%) 0.318
Lymphocyte(G) (1:> 1.6/0:< 1.6)109/L 349 (50.8%)/338 (49.2%) 239 (49.5%)/242 (50.3%)
Missing 6 (1%)
110 (53.4%)/96 (46.6%) 0.405
N/L(G) (1:> 1.5/0:< 1.5) 343 (50%)/343 (50%) 238 (49.6%)/242 (50.4%)
Missing 7 (1%)
105 (51%)/101 (49%) 0.830
Platelet(G) (1:> 187/0:< 187)109/L 330 (48%)/357 (52%) 234 (48.6%)/247 (51.4%)
Missing 6 (1%)
96 (46.6%)/110 (53.4%) 0.677
N/P(G) (1:> 0.02/0:< 0.02) 350 (50.5%)/343 (49.5%) 242 (49.7%)/245 (50.3%) 108 (52.4%)/98 (47.6%) 0.561
ALP(G) (1:> 82/0:< 82)U/L 351 (51.2%)/334 (48.8%) 237 (49.5%)/242 (50.5%)
Missing 8 (2%)
114 (55.3%)/92 (44.7%) 0.182
APTT(G) (1:> 26.6/0:< 26.6) S 347 (50.7%)/337 (49.3%) 238 (49.7%)/241 (50.3%)
Missing 8 (2%)
109 (53.2%)/96 (46.8%)
Missing 1
0.453
CEA (ng/ml) 3.56 (2.01–5.10) 2.85 (2.65–3.04) 5.64 (0.44–11.72) 0.121
CYFRA211 (ng/ml) 2.44 (2.33–2.54) 2.41 (2.29–2.52) 2.52 (2.26–2.79) 0.361
NSE (ng/ml) 15.78 (15.34–16.22) 15.76 (15.24–16.28) 15.82 (15.00–16.64) 0.914
Pathology (Squamouscell/Neuroendocrine /Adenosquamous/Small cell/Adenocarcinoma/other) 651 (95.2%)/7 (1%)/7 (1%) /7 (1%)/4 (0.6%)/8 (1.2%) 453 (95%)/4 (0.8%)/5 (1%) /7 (1.5%)/4 (0.8%)/4 (0.8%)
Missing 10 (2%)
197 (95.6%)/3 (1.5%)/2 (1%) /0 (0%)/0 (0%)/4 (1.9%) 0.082
Grade (I/ I-II/ II/ II-III/ III) 32 (5%)/36 (5.6%)/240 (37.3%)/250 (38.9%) /85 (13.2%) 26 (5.7%)/26 (5.7%)/170 (37%)/178 (38.8%) /59 (12.9%)
Missing 28 (6%)
6 (3.3%)/10 (5.4%)/70 (38%) /72 (39.1%)/26 (14.1%)
Missing 22 (10%)
0.760
Concurrent Cancers (1:Yes/ 0:No) 49 (7.1%)/640 (92.9%) 36 (7.5%)/447 (92.5%)
Missing 4
13 (6.3%)/193 (93.7%) 0.746
Maximum Diameter Of Tumor (cm) 3.06 (2.94–3.18) 3.10 (2.96–3.25) 2.98 (2.77–3.19) 0.339
Depth of tumor invasion (cm) 3.33 (3.23–3.43) 3.38 (3.28–3.45) 3.21 (3.00–3.41) 0.096
Lymph-vascular Space invasion (1:Yes/ 0:No) 134 (19.5%)/554 (80.5%) 96 (19.9%)/386 (80.1%)
Missing 5
38 (18.4%)/168 (81.6%) 0.676
Neural invasion (1:Yes/ 0:No) 75 (89.1%)/612 (10.9%) 67 (13.9%)/414 (86.1%)
Missing 6
18 (8.7%)/188 (91.3%) 0.051